Replies to post #128868 on PharmaCyte Biotech Inc (PMCB)

[tntgraham]

That’s what I figured, are they done

[livendi]

nice,thats what i was hoping for

[$Pistol Pete$]

$PMCB CEO sells block shares for .005

Let's look at KENNETH WAGGONER CEO OF PHARMACYTE attributes

A CEO of a penny stock

Was associated with 2 scam companies in the past.

Misleads investors with PR wording.

A lawyer, not a businessman and definitely not a Bio Tech person.

Has not been able to generate capital gains for Long term stockholders in PMCB since he joined the company in 2014.

Never has he purchased any shares in PMCB.

PMCB currently has 1.7 billion shares outstanding, without yet submitting an IND.

KW received over 1 million dollars in cash and stock and stock options in 2018, and the company not as yet have an approved product or filed an IND yet:

As Chief Executive Officer, President and General Counsel, Director at PHARMACYTE BIOTECH INC, Kenneth L. Waggoner made $1,004,360 in total compensation. Of this total $375,000 was received as a salary,$312,800 was received in stock options, $316,560 was awarded as stock. This information is according to proxy statements filed for the 2018 fiscal year.

[Jimmy Joe]

Shares were sold last week in order to raise capital to fund the company’s operation.

/quote]

Funny how the "company" cannot find a means by which to obtain money or support from fund sources that do such things. There is nothing in place from any lenders such as for example a Lincoln Park.

The fact is not one of them will touch this thing with a 50 foot pole.
All they have to do is look at ongoing operations and realize this group either doesn't know how to go about running the company with this CiaB technology as its primary platform, or the "company" doesn't care bacause they all make hefty paychecks without having to perform.

So now, they sold shares in order to raise capital? Wow, what a bunch of bullshit.

How many years have they been afforded the opportunity to figure this out and they just can't seem to do it? The same story plays out year after year.

The replicate growth of of this cell line means nothing without data on how effective the cell line is in treating the cancer. There is no data on that.

And if you may, please post your confirmation source that selling of shares is to drum up money needed for the operation of the company.

Or is that just the salary portion of the "operation"?

This whole thing smells to high heaven.
The fish rots from the head.
Everything from COVID test kits to TRY to take advantage of a pandemic, to submitting an IND for a phase 2B that should actually be a phase 1.
What a cluster fuk.

Free the pinky pumps.
What a crap investment with an even crappier CEO at the helm.
Let's get that IND PR out there ASAP, shall we boyz?